Protocol Ledger

NCT04901936 · Phase II · RECRUITING

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventional Phase II clinical trial protocol NCT04901936 sponsored by Apellis Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-02-04 Enrollment: 12 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04901936
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)12 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04901936
Protocol FieldVerified Registry Value
NCT IdentifierNCT04901936
Consolidated Lead SponsorApellis Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment12 participants (ESTIMATED)
Registered Start Date2021-02-04
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI